Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus

Lancet

Volumn 350, Issue 9086, 1997, Pages 1199-1204

  Acerini, Carlo L ^a   Patton, Caroline M ^a   Savage, Martin O ^b   Kernell, Anna ^c   Westphal, Otto ^d   Dunger, David B ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; RECOMBINANT PROTEIN; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; BLOOD; CLINICAL TRIAL; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TIME;

ADOLESCENT; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; PATIENT COMPLIANCE; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0031586495     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06467-2     Document Type: Article

References (30)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
2. Mann NP, Johnston DI. Total glycosylated haemoglobin (HbA1) levels in diabetic children. Arch Dis Child 1982; 57: 434-37.
3. Kernell A, Dedorsson I, Johansson B, et al. Prevalence of diabetic retinopathy in children and adolescents with IDDM. Diabetologia 1997; 40: 307-10.
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-88.
5. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP. Increased overnight growth hormone concentrations in diabetes compared with normal adolescents. J Clin EndocrinolMetab 1990; 71: 1356-62.
6. Dunger DB, Edge JA, Pal R, Taylor AM, Holly JMP, Matthews DR. Impact of increased growth hormone secretion on carbohydrate metabolism in adolescents with diabetes. Acta Pediatr Scand 1991; 337 (suppl): 69-77.
7. Edge JA, Matthews DR, Dunger DB. Failure of current insulin regimens to meet the overnight insulin requirements of adolescents with insulin-dependent diabetes. Diabetes Res 1990; 15: 109-12.
8. Dunger DB. Insulin and insulin-like growth factors in diabetes mellitus. Arch Dis Child 1995; 72: 469-71.
9. Shisko PI, Kovaler PA, Gonsharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes 1992; 41: 1042-49.
10. Cheetham TD, Clayton KL, Taylor AM, Holly J, Matthews DR, Dunger DB. The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol 1994; 40: 515-22.
11. Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with Type 1 (insulin dependent) diabetes mellitus. Diabetologica 1993; 36: 678-81.
12. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 1040-45.
13. Cheetham TD, Holly JMP, Clayton K, Cwyfan-Hughes S, Dunger DB. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type I diabetes. Diabetic Med 1995; 12: 885-92.
14. Jeppsson J-O, Jerntorp P, Almer L-O, Persson R, Ekberg G, Sundkvist G. Capillary blood on filter paper for determination of HbA1c by ion exchange chromatography. Diabetes Care 1996; 19: 142-45.
15. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicentre trial. N Engl JMed 1984; 311: 365-72.
16. Quattrin T, Thrailkill K, Baker L, et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM: effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 1997; 20: 374-80.
17. Thrailkill K, Quattrin T, Baker L, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. J Clin Endocrinol Metab 1997; 82: 1181-87.
18. Taylor AM, Dunger DB, Preece MA, Holly JMP, Smith CP, Wass JAH. The growth hormone independent insulin like growth factor I binding protein BP-28 is associated with serum insulin like growth factor-I inhibitory bioactivity in adolescent insulin dependent diabetes. Clin Endocrinol 1990; 32: 229-39.
19. Cheetham TD, Taylor A, Holly JMP, Clayton K, Cwyfan-Hughes S, Dunger DB. The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1994; 142: 367-74.
20. Zenobi PD, Glatz Y, Keller A, et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994; 131: 251-57.
21. Moses AC, Young SG, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 1996; 45: 91-100.
22. Crowne EC, Samra JS, Cheetham T, Watts A, Holly JMP, Dunger DB. Recombinant human IGF-I abolishes changes in insulin requirements consequent upon growth hormone (GH) pulsatility in young adults with type 1 diabetes mellitus. Metabolism (in press).
23. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin: dose-response relationships in healthy young and middle aged adults. J Clin Invest 1994; 93: 1131-39.
24. Zapf J, Schoenle E, Waldvogel M, Sand I, Froesch ER. Effect of trypsin treatment of rat adipocytes on biological effects of binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 1981; 113: 605-09.
25. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995; 18: 1415-27.
26. Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin resistant type II diabetic patients. Diabetes 1994; 43: 369-74.
27. Merimee TJ, Zapf J, Foresch ER. Insulin-like growth factors: studies in diabetics with and without retinopathy. N Engl J Med 1983; 309: 527-30.
28. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor I acts as an agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282-91.
29. Wang Q, Dills DG, Klein R, Klein BEK, Moss SE. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 1995; 44: 161-64.
30. Gerich JE. Role of growth hormone in diabetes mellitus. N Engl J Med 1984; 310: 848-49.